Pfizer (PFE) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Pfizer (PFE) over the past year, gaining 31.2% versus a gain of 6.6%. Over five years, REGN leads with a +33.7% price change compared with -32.5% for PFE. Pfizer is the larger company by market cap ($158.56 billion vs $76.14 billion), about 2.1 times the size, while Regeneron Pharmaceuticals is growing revenue faster (+1.0% vs -1.6%).
On valuation, Pfizer trades at a lower forward P/E (9.6x vs 12.0x for Regeneron Pharmaceuticals). Pfizer offers the higher dividend yield (6.18% vs 0.49%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 12.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PFE | REGN |
|---|---|---|
| Share price | $27.82 | $739.57 |
| Market cap | $158.56B | $76.14B |
| 1-day change | -0.64% | -0.34% |
| YTD return | +12.45% | -4.18% |
| 1-year return | +6.59% | +31.16% |
| 5-year return | -32.51% | +33.68% |
| P/E ratio (TTM) | 36.61 | 18.29 |
| Forward P/E | 9.60 | 12.03 |
| EPS (TTM) | $0.76 | $40.44 |
| Dividend yield | 6.18% | 0.49% |
| Annual dividend | $1.72 | $3.64 |
| Revenue (latest FY) | $62.58B | $14.34B |
| Revenue growth (YoY) | -1.65% | +0.99% |
| Net income (latest FY) | $7.77B | $4.50B |
| Gross margin | 74.33% | — |
| Operating margin | — | 24.95% |
| Net margin | 12.42% | 31.41% |
| 52-week high | $29.21 | $859.34 |
| 52-week low | $23.62 | $541.00 |
| Distance from 52-week high | -4.76% | -13.94% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.92% | +15.77% |
| Average volume | 35.94M | 739.67K |
| Shares outstanding | 5.70B | 101.14M |
| Employees | 75,000 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pfizer is about 2.1 times larger than Regeneron Pharmaceuticals by market value ($158.56B vs $76.14B).
- REGN has outperformed PFE by 24.6 percentage points over the past year.
- Pfizer trades at a higher earnings multiple (36.6x vs 18.3x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (6.18% vs 0.49%).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 12.4 cents for Pfizer.
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
PFE vs REGN FAQ
Which is bigger, Pfizer or Regeneron Pharmaceuticals?
Pfizer (PFE) is larger, with a market capitalization of $158.56B compared with $76.14B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, PFE or REGN?
REGN returned +31.16% over the past 12 months, compared with +6.59% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PFE or REGN?
REGN has the lower trailing P/E at 18.3, versus 36.6 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Pfizer or Regeneron Pharmaceuticals?
Pfizer has the higher yield at 6.18%, compared with 0.49% for Regeneron Pharmaceuticals.
Are Pfizer and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.